Search hospitals > New York > Bronx
Montefiore Medical Center
Claim this profileBronx, New York 10467
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Parotid Gland Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
1099 reported clinical trials
103 medical researchers
Summary
Montefiore Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of Cancer, Breast Cancer, Parotid Gland Cancer, Non-Small Cell Lung Cancer, Lung Cancer and other specialties. Montefiore Medical Center is involved with conducting 1,099 clinical trials across 1,276 conditions. There are 103 research doctors associated with this hospital, such as Lisa Gennarini, MD, Sanjay Goel, Nitin Ohri, and David J Altschul, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
FGFR3 positive
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Lisa Gennarini, MDMontefiore Medical Center - Moses Campus5 years of reported clinical research
Expert in Cancer
Expert in Adult T-Cell Leukemia/Lymphoma
57 reported clinical trials
117 drugs studied
Sanjay GoelMontefiore Medical Center5 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
21 reported clinical trials
30 drugs studied
Nitin OhriMontefiore Medical Center-Einstein Campus9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
44 drugs studied
David J Altschul, MDMontefiore Medical Center3 years of reported clinical research
Studies Intracranial Aneurysm
Studies Pararenal Aneurysms
17 reported clinical trials
16 drugs studied
Clinical Trials running at Montefiore Medical Center
Lung Cancer
Multiple Myeloma
Lymphoma
Bladder Cancer
Breast Cancer
Post-Implantation Syndrome
Non-Small Cell Lung Cancer
Stroke
Liver Cancer
Chronic Kidney Disease
Zongertinib
for Lung Cancer
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein. Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
Recruiting2 awards Phase 39 criteria
Dato-DXd + Pembrolizumab
for Advanced Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Recruiting2 awards Phase 313 criteria
Pembrolizumab + Berahyaluronidase
for Non-Small Cell Lung Cancer
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Montefiore Medical Center?
Where is Montefiore Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Montefiore Medical Center accept?
What awards or recognition has Montefiore Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.